Shenyan Biology completed the B round of financing of 100 million yuan

Shenyan Bio is a technology company in the field of biotechnology. It is committed to solving a series of key problems in the industrialization of individualized cancer immunotherapy step by step through the cross-integration of computer, electronics, automation, materials, chemical and other disciplines and life sciences. Technical problems, and finally obtain a highly automated, precise, stable and reliable individualized cancer immunotherapy solution for a wide range of cancers with significant curative effect. Recently, it completed the B round of financing of 100 million yuan. This round of financing was led by Eight Roads Capital, followed by Ninefitte Investment and Juke Investment. An international well-known industrial group, an old shareholder, continued to follow up. Xinghan Capital acted as the exclusive financial advisor.

This article is reproduced from:
This site is for inclusion only, and the copyright belongs to the original author.

Leave a Comment

Your email address will not be published.